In the rapidly evolving field of gene therapy, optimizing the production of adeno-associated viral vectors (AAVs) is essential for success. Our latest white paper dives into the advantages of using transient transfection systems for AAV production, offering key insights into improving scalability, efficiency, and cost-effectiveness. Whether you're in early development or scaling for clinical trials, this resource provides valuable strategies to help you streamline production and ensure high-quality outcomes. Discover how industry leaders like Viralgen are shaping the future of AAV manufacturing.
